4yr
Influence of progesterone receptor on metastasis and prognosis in breast cancer patients with negative HER-2
Source : https://gs.amegroups.com/article/view/87989/html
The dramatic increase in breast cancer survival in recent years (since the 1970s) has been attributed to the discovery of hormone receptors (HRs), human epidermal factor growth receptor 2 (HER-2) and the widespread use of endocrine and targeted therapies.
Conclusions: ER−/PR subtype had a high proportion of stage IV patients. Meanwhile, such subtype breast cancer had similar clinicopathological characteristics, metastatic models (prefers to visceral metastasis), similar even worse prognosis compared with TNBC.
• Source: Gland Surgery
• Conclusions: “ER−/PR+ subtype had a high proportion of stage IV patients. Meanwhile, such subtype breast cancer had similar clinicopathological characteristics, metastatic models (prefers to visceral metastasis), similar even worse prognosis compared with TNBC.”
• Little research assesses the clinicopathology and prognosis of single-hormone receptor subtypes in the context of metastatic breast cancer. In the current study, investigators used the Surveillance, Epidemiology and End Results (SEER) database to assess this issue.
• In the current study, the single progestin-positive subtype represented % in HER-2 negative patients was noted in 1%–4% in all breast cancer patients. These patients exhibit increased tumor mass, higher grade tumors, and higher HER-2 expression, according to previous studies. Tumors were aggressive, with single hormone receptor-positive (e.g., PR negativity) breast cancer an independent risk factor for visceral metastases.
• In the current study, investigators noted that ER−/PR+ patients and TNBC patients exhibited a comparable metastasis pattern, with both developing visceral metastasis but not bone metastasis.
• Limitations of the current study include the SEER database not reflecting endocrine or targeted therapy. Furthermore, there is an incomplete record of site of metastasis of stage IV metastases in the SEER database.